key: cord-1037618-ayhpm8i3
authors: Jungbauer, Christof; Weseslindtner, Lukas; Weidner, Lisa; Gänsdorfer, Simon; Farcet, Maria R.; Gschaider-Reichhart, Eva; Kreil, Thomas R.
title: Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations
date: 2020-06-21
journal: bioRxiv
DOI: 10.1101/2020.06.21.163444
sha: 65f744f76ed6aff2387ea9922e808fa228c03756
doc_id: 1037618
cord_uid: ayhpm8i3

Transfusion of SARS-CoV-2 convalescent plasma is a promising treatment for severe COVID-19 cases, with success of the intervention based on neutralizing antibody content. Measurement by serological correlates without biocontainment needs, and an understanding of donor characteristics that may allow for targeting of more potent donors would greatly facilitate effective collection.

donor characteristics that may allow for targeting of more potent donors would greatly facilitate 23 effective collection. scores of 3 to 6, who had a mean NT50 antibody titer of 1:696. While these results may seem to 78 support the notion of higher titers with increased disease severity, the numbers of CP donors in 79 higher WHO scores in this study are too low to determine significance. For CP donor age ( Figure   80 2A), the NT50s were significantly correlated (p = 0.0019), yet with little predictive value (R 2 = 81 0.09466) and targeting advance age donors for CP collection may therefore not be very effective.

On average, the CP collected from male donors (N = 61) had a significantly higher mean NT50 83 than from female donors (N=38), yet whether the mean titer difference of 1:220 has any 84 functional relevance is questionable ( Figure 2B ). 

Challenges of convalescent plasma infusion 135 therapy in Middle East respiratory coronavirus infection: a single centre experience

Use of convalescent plasma therapy 138 in SARS patients in Hong Kong

Treatment of 5 Critically Ill Patients With 140 COVID-19 With Convalescent Plasma

Effectiveness of convalescent plasma therapy in 142 severe COVID-19 patients

Convalescent plasma treatment of 145 severe COVID-19: A matched control study. medRxiv

An EU programme of COVID-19 convalescent plasma collection and 147 transfusion

Investigational COVID-19 Convalescent Plasma; Guidance 149 for Industry

Serology assays to manage COVID-19. Science

Antibody responses to SARS-CoV-2 in patients 152 of novel coronavirus disease

WHO reference number WHO/WHO/R&D Blueprint (CoVID)/2020.5; available at 155